Exploratory Study on the Paclitaxel + S-1 + Oxaliplatin (PSOX) for Locally Advanced or Advanced Gastric Cancer
Explore the Efficiency and Safety of Paclitaxel + S-1 + Oxaliplatin (PSOX) Chemotherapy in the Patients with Locally Advanced or Advanced Gastric Cancer
Gastric Cancer
DRUG: Paclitaxel + S-1 + Oxaliplatin
Objective response rate(ORR), The sum of complete remission (CR) rate and partial remission (PR) rate., 2 years
Progression-free survival(PFS), From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months, 2 years|Overall survival(OS), From date of enrollment until the date of death from any cause, assessed up to 60 months, 2 years|Disease control rate(DCR), The sum of CR rate, PR rate and stable disease(SD) rate. Response will be measured through first-line treatment completion, up to 1 year, 2 years
To assess the Efficiency and safety of Paclitaxel + S-1 + Oxaliplatin(PSOX) in the Patients with Locally Advanced or Advanced Gastric Cancer